Rockville-based Human Genome Sciences Inc., which last week rejected an unsolicited $2.6 billion acquisition offer by GlaxoSmithKline PLC, reported higher revenue and cut losses on sales of its new lupus drug.
Human Genome Sciences had first-quarter revenue of $47.1 million, compared with $26.6 million a year earlier. Benlysta sales accounted for $32.1 million in revenue. Sales of its anthrax treatment to the U.S. government stockpile contributed $6.1 million.
{iframe}http://www.bizjournals.com/washington/news/2012/04/24/human-genome-cuts-losses.html?ana=e_wash_rdup&s=newsletter&ed=2012-04-25{/iframe}